GlassScriptPhysician profile
Ryan Cantville
NPI 1508156795
$87,321.52
in general payments reported to CMS, 2019-2025
28 companies · $734 in 2025
The $734 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,786 · 2020: $174 · 2021: $23K · 2022: $823 · 2023: $22K · 2024: $38K · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $5,693 · Food and Beverage: $4,506 · Consulting Fee: $3,087 · Honoraria: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,000.00 |
| Travel and Lodging | $5,692.86 |
| Food and Beverage | $4,506.43 |
| Consulting Fee | $3,087.00 |
| Honoraria | $2,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $76,766.65 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $3,789.82 | 2024 | |
| Neos Therapeutics, LP | $2,487.18 | 2019-2022 | |
| Corium, LLC | $1,562.49 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $502.21 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $355.71 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $296.31 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Pfizer INC. | $203.52 | 2019-2025 | |
| Tris Pharma INC | $187.56 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $162.41 | 2021-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $162.02 | 2019-2022 | |
| Sanofi Pasteur INC. | $119.17 | 2019-2025 | |
| Sobi, INC | $117.74 | 2019-2024 | |
| Alk-Abello, INC | $100.61 | 2025 | Neffy, Grastek, Odactra |
| Seqirus USA INC | $98.01 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $73.31 | 2023-2025 | Ycanth |
| Vertical Pharmaceuticals, LLC | $68.39 | 2019-2025 | Relexxii |
| Rhodes Pharmaceuticals L.P. | $47.18 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.37 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $28.73 | 2025 | Jornay Pm |
| Kaleo, INC. | $27.60 | 2021-2022 | |
| Genentech USA, INC. | $24.82 | 2019-2020 | |
| Abbott Laboratories | $23.12 | 2024 | Id Now Strep A 2 |
| Sanofi-Aventis U.S. LLC | $20.96 | 2025 | |
| Acadia Pharmaceuticals INC | $16.65 | 2023 | Daybue |
| Adlon Therapeutics L.P. | $15.97 | 2019 | |
| Shire North American Group INC | $15.77 | 2019 | |
| Hologic Sales and Service, LLC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cantville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.